FLT3 and acute myeloid leukemia: While intensive chemotherapy plus a FLT3 inhibitor is now standard of care for younger, fit patients with newly diagnosed FLT3-mutated AML [14, 15], the role of frontline FLT3 inhibitors in older, unfit patients is not well-established nor is the optimal way to integrate these agents into lower-intensity frontline regimens.